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a b s t r a c t 
Background: There is considerable heterogeneity in antidepressant treatment response across individuals. As peo- 
ple with depression may manifest different symptom profiles, we hypothesized that the constellation of specific 
depressive symptoms might explain some of the heterogeneity in antidepressant treatment response. To assess 
this hypothesis, we examined symptom-specific remission related to antidepressant vs placebo treatment among 
those with and without a treatment response. 
Methods: Data were from 19 randomized controlled trials ( n = 7,344). Depressive symptoms were assessed with 
the 17-item Hamilton Depression Rating Scale (HDRS-17). Data on treatment were dichotomized into active 
treatment vs placebo. Treatment response was defined as ≥ 50% reduction in the HDRS-17 sum score during trial 
follow-up. Associations of antidepressant treatment with symptom remission were assessed in logistic regression 
models conducted separately for each symptom, adjusting for age, sex, follow-up time, and the presence of the 
symptom at baseline. Treatment responders and non-responders were analyzed separately. We also assessed tra- 
jectories of symptom remission across the trial follow-up in both treatment conditions among responders and 
non-responders. 
Results: There were no coherent differences in symptom remission between the antidepressant and placebo 
conditions either among responders (OR = 0.75–1.28) or non-responders (OR = 0.49–1.35). Likewise, there were 
no coherent differences between the remission trajectories either among treatment responders or non-responders. 
Limitations: Treatment responders and non-responders were analyzed separately, which may have introduced 
bias that could affect the validity of our findings. 
Conclusions: We observed no consistent evidence that treatment response to antidepressants depends on the 



























Antidepressants are widely used to treat major depressive disorder.
eta-analytic evidence suggests that antidepressants are moderately ef-
ective compared to placebo, with effect sizes for efficacy ranging be-
ween 1.37 and 2.13 (odds ratios) ( Cipriani et al., 2018 ). However, there
s substantial heterogeneity in the treatment response, indicating that
ome individuals benefit more than others. Up to a half of treated indi-
iduals may not have a clinically significant treatment response ( Corey-
isle et al., 2004 ; Gueorguieva, 2011 ; Thomas et al., 2013 ), which
s commonly defined as a reduction of ≥ 50% in the total depression∗ Corresponding author. 
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ecco, 2001 ). Part of the antidepressant treatment effect may also be
xplained by a placebo effect ( Furukawa et al., 2016 ). 
Despite the effectiveness of antidepressants, it is still unclear how
ntidepressants work, and which factors determine individual differ-
nces in treatment response. Symptom-specific analyses of antidepres-
ants have suggested that the antidepressant treatment effect may be
reater for some depressive symptoms than others ( Hieronymus et al.,
016a ). For example, treatment effect may be more marked for ‘de-
ressed mood’ compared to the sum of all symptoms. Other studies have
hown differences in risk factors and social impairment between specificpril 2021 
ticle under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
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Fig. 1. Associations of antidepressant treat- 
ment (vs placebo) with presence of a symp- 
tom at follow-up among treatment respon- 
ders. 
Abbreviations: OR, odds ratio; CI, confi- 
dence interval n = 3304 (active treatment 


































































c  ymptoms of depression ( Fried and Nesse, 2014 ; García-Velázquez et al.,
019 ). Together these results suggest that the constellation of specific
epressive symptoms might help to explain some of the heterogeneity
n antidepressant treatment response. 
However, a more detailed symptom-specific analysis of treatment-
esponse heterogeneity needs to examine the symptom trajectories as-
ociated with antidepressant treatment versus placebo among those who
chieve clinically significant treatment response. These trajectories can
hen be compared to symptom trajectories among those who do not
chieve treatment response in order to assess whether any differences
etween antidepressant treatment and placebo are specifically related
o treatment response versus non-response. We used data from 19 ran-
omized controlled trials to examine these symptom-specific associa-
ions related to antidepressant treatment vs placebo treatment among
hose with and without a treatment response. 
. Methods 
Data were from 19 industry-sponsored, US Food and Drug Admin-
stration (FDA)-registered, placebo/active treatment-controlled phase 3
fficacy trials among adult patients with major depression for parox-
tine (GSK/003, GSK/009, GSK/115, GSK/448, GSK/449, GSK/487,
SK/810, GSK/874, HMATa, HMATb, HMAYa, HMAYb, HMCV), du-
oxetine (HMAH, HMATa, HMATb, HMAYa, HMAYb, HMBHa, HMBHb,
MBV, HMCB, HMCR, HMCV), fluoxetine (GSK/115), imipramine
GSK/003) and escitalopram (HMCR) from GlaxoSmithKline (Brentford,
K) and Eli Lilly (New York, NY). We included all randomized pa-
ients with baseline assessment and at least one post-baseline assess-
ent ( n = 7344). Depressive symptoms were measured with the 17-
tem Hamilton depression rating scale (HDRS-17, see Fig. 1 for list of
ymptoms) on scales ranging 0–4 or 0–2 (greater values indicate greater
everity). To assess post-treatment symptom remission, the responses to
DRS-17 items were dichotomized into 0 (symptom not present, i.e., an
ndication of remission) vs ≥ 1 (symptom present, i.e., no remission) at
he last available assessment for each patient. Data on treatment were di-2 hotomized into active antidepressant treatment vs placebo. Treatment
esponse was defined as ≥ 50% decrease in the HDRS-17 sum score be-
ween baseline and the last available assessment for each patient. 
Associations of antidepressant treatment with symptom remission
ere assessed in a series of logistic regression models where antide-
ressant treatment (vs placebo) was used to predict the presence of
 symptom at the follow-up (i.e. each patient’s last available assess-
ent). Separate models were conducted for each HDRS-17 symptom.
ll models were adjusted for age, sex, follow-up time and the presence
f the outcome symptom at baseline. Treatment responders ( n = 3304)
nd non-responders ( n = 4040) were analyzed separately. To illus-
rate the trajectories of symptom remission associated with antidepres-
ant treatment, we plotted marginal predictions for the probability of
ach symptom being present at each assessment time in both treat-
ent conditions. These predictions were obtained from sex- and age-
djusted population-averaged random-intercept logistic multilevel re-
ression models in which the presence of a symptom was predicted by
he treatment condition, time indicator (assessment week coded as a cat-
gorical variable) and an interaction term between the treatment con-
ition and the time indicator. 
As sensitivity analyses, we conducted all analyses separately among
atients receiving SSRI (paroxetine, fluoxetine and escitalopram) vs
lacebo and among patients receiving SNRI (duloxetine) vs placebo. 
. Results 
Of the 7344 patients, 4542 (62%) were women. The mean age was
5.4 years (SD = 15.5). Follow-up times (between baseline and last avail-
ble assessment for each patient) varied between 1 and 12 weeks, with
 mean of 9 weeks (SD = 2.3) among treatment responders and 8 weeks
SD = 3.2) among non-responders. A total of 2604 (79%) responders and
629 (65%) non-responders received antidepressant treatment. 
In symptom-specific analyses among treatment responders, the over-
ll pattern of results with most of the HDRS-17 symptoms suggested no
oherent differences between the antidepressant and placebo conditions


























































































































t follow-up: no specific symptom cluster or domain (e.g., cognitive, af-
ective, somatic) showed higher or lower likelihood of remission asso-
iated with antidepressant treatment, although associations with some
ndividual symptoms were observed. Antidepressant treatment was as-
ociated with higher probability of remission in depressed mood and
gitation, but lower probability of remission in early-night insomnia,
sychic anxiety, and general somatic symptoms ( Fig. 1 ). The trajecto-
ies of symptom remission between antidepressant vs placebo conditions
ere mostly overlapping ( Fig. 2 ), although there were some symptom-
pecific differences corresponding to the results comparing follow-up vs
aseline (e.g., higher probability of remission in depressed mood and
gitation, but lower probability of remission in insomnia (early in the
ight), psychic anxiety and general somatic symptoms). 
Similarly to those with treatment response, the symptom-specific
attern of results among patients with no treatment response suggested
o coherent differences: antidepressant treatment was not associated
ith remission in any specific domain of depressive symptoms, although
ssociations of antidepressant treatment with remission in individual
ymptoms were observed. Antidepressant treatment was associated with
igher probability of remission in depressed mood, guilt, suicidality,
ifficulties in work and activities, agitation and genital symptoms, but
ower probability of remission in psychic and somatic anxiety as well
s hypochondria ( Supplementary Fig. 1 ). Among non-responders, the
ifferences in the trajectories between the antidepressant vs placebo
onditions were somewhat more pronounced than among treatment re-
ponders. For instance, we observed higher probability of remission in
epressed mood, guilt and suicidality, and lower probability of remis-
ion in anxiety and hypochondria in the antidepressant condition among
hose with no treatment response. However, as with responders, no sys-
ematic differences between the remission trajectories were observed
mong non-responders ( Supplementary Fig. 2 ). 
The results were similar when patients receiving SSRI and SNRI (vs
lacebo) were analyzed separately ( Supplementary Figs. 3–10 ). 
. Discussion 
In this analysis of 7344 patients from 19 randomized antidepres-
ant trials, we did not observe systematic differences in the remis-
ion of specific depressive symptoms when comparing antidepressant vs
lacebo conditions among those with or without a treatment response
i.e., ≥ 50% decrease in total depression score). Most of the symptoms
howed no differences between antidepressant and placebo groups, and
he differences that were observed were not uniform: some symptoms
howed higher and others lower likelihood of remission in antidepres-
ant treatment versus placebo. Furthermore, the trajectories of symp-
om remission between antidepressant versus placebo conditions were
ostly overlapping throughout the course of the treatment. The asso-
iations were largely similar among those with no treatment response
i.e., < 50% decrease in total depression score), which further provided
vidence against symptom-specific associations that would specifically
escribe a more successful treatment response associated with antide-
ressant treatment. 
Recent research based on network models and symptom-specific
nalysis of depressive symptoms has suggested that specific symp-
oms of depression may be characterized by different etiology, tem-
oral dynamics, response to treatment, and associations with social
mpairment ( Fried and Nesse, 2015 , 2014 ; Hieronymus et al., 2016b ;
omulainen et al., 2020 ). We therefore hypothesized that symptom-
pecific associations might also help to explain individual differences in
reatment response to antidepressants as compared to placebo response.
hat is, a successful antidepressant treatment might act specifically on
ertain symptoms more than others, which would differentiate the treat-
ent response to antidepressants from the corresponding placebo effect.
e observed no systematic evidence to support this hypothesis, as the
reatment response and placebo response were mostly similar, and theifferences that were observed were mixed. W  
3 Our result is in agreement with a recent meta-analysis that found
ittle evidence for the presence of subpopulations that would bene-
t from antidepressant treatment above the average treatment effect
 Volkmann et al., 2020 ). However, it must be emphasized that our analy-
is focused specifically on the symptom differences between antidepres-
ant treatment and placebo among those with a treatment response, so
he current analysis should not be interpreted as an analysis of the effec-
iveness of antidepressants. Rather, we were interested in the symptom-
pecific patterns related to successful treatment response. 
Some limitations need to be acknowledged. First, at least one study
as suggested that the pattern of depressive symptoms in a depressive
pisode may depend on the events and life circumstances that triggered
he depressive episode (e.g., death of a loved one, ending a romantic
elationship, personal failure, or chronic stress) ( Keller et al., 2007 ).
hese life events may also influence the probability of treatment re-
ponse and recovery. We did not have data on the background variables
elated to the onset of depression, so we could not adjust for these po-
ential confounding factors. Second, although our data were from ran-
omized trials, we assessed the associations of antidepressant treatment
ith symptom-level remission separately among those with and without
reatment response. This naturally makes the study design not random-
zed, and the selection of only treatment responders in the analysis may
ave introduced bias that could have affected the validity of our find-
ngs. Third, symptom remission was assessed with dichotomous mea-
ures (symptom absent vs present) that did not capture more detailed
eductions in symptom severity; while complete symptom remission is
he desired outcome of antidepressant treatment, even smaller reduc-
ions in symptom severity may be relevant. Fourth, the patients were
dults with major depressive disorder who had to meet the standard
ligibility criteria for antidepressant trials, which may limit the gen-
ralizability of our findings to more natural clinical settings. Fifth, we
onducted the analyses in the intention-to-treat population where the
ollow-up times between treatment initiation and assessment of symp-
om remission ranged from 1 to 12 weeks. It is possible that not all
articipants had sufficient time to experience consistent symptom-level
emission, if more systematic patterns of symptom remission only occur
t longer time intervals. Finally, although we additionally analyzed pa-
ients receiving SSRI and SNRI (vs placebo) separately, we did not dis-
inguish between paroxetine, duloxetine, fluoxetine, imipramine, and
scitalopram. However, different antidepressants may act differently on
pecific depressive symptoms. 
In conclusion, we did not find evidence to suggest that the treat-
ent response to antidepressants would be characterized by specific
epressive symptoms as compared to the symptom-specific patterns of
he placebo effect, or the corresponding difference among those with no
reatment response. These findings suggest that a successful treatment
esponse to antidepressants may not depend on the specific symptoms
hat constitute the person’s major depressive disorder diagnosis. 
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